medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2009, Number 4

<< Back Next >>

Rev Inst Nal Enf Resp Mex 2009; 22 (4)

Underglycosylated MUC1 expression in lung adenocarcinoma and its metastases

Atzin MJA, Saldaña VAK, Bernal D, Vázquez ME, Serrato PA, Gorocica RP

Language: Spanish
References: 36
Page: 295-303
PDF size: 137.12 Kb.


ABSTRACT

MUC1 is an O-glycoprotein expressed at the apex of normal epithelial cells, but its distribution, structure and immunogenicity often change in adenocarcinoma cells and these changes are related to tumor behavior. O-glycosylation of MUC1 in neoplastic cells is truncated, leading to Tn antigen (MUC1-Tn) or T antigen (MUC1-T). Both MUC1-Tn and MUC1-T can be immunogenic and possibly can break tolerance to neoplastic cells to favor inflammatory infiltrate in the tumor area. The aim of this work was to identify the saccharidic features of underglycosylated MUC1 in patients with pulmonary adenocarcinoma. The study comprised 5 patients with clinical and histopathological diagnosis of stage IV pulmonary adenocarcinoma. Expression of MUC1-Tn and MUC1-T was determined by immunohistochemistry by using MUC1 antibody, clone DF3, to non-glycosylated or underglycosylated forms of MUC1. Additionally, lectins from Vicia villosa and Arachis hypogea were used to identify Tn and T antigen, respectively. Evaluation was done through light microscopy and image digital analysis. Results showed increased expression of underglycosylated MUC1 on cell surface and cytoplasm of primary tumor cells, which was positively correlated with Tn antigen expression, but not with T antigen expression. Concerning to metastases, a positive correlation was found between MUC1 expression and either Tn or T antigen, excepting in brain, heart and diaphragm tissues, which suggests that MUC1 expression analysis in lung adenocarcinoma may be an important predictor for prognosis.


REFERENCES

  1. Gurrola-Díaz CM, González-Santiago AE, Troyo-Sanromán R, Mendoza-Topete LA. Lung cancer histological types and diagnostic methods in a tertiary care facility. Gac Med Mex 2009;145:97-101.

  2. Brambilla E. Classification of broncho-pulmonary cancers (WHO 1999). Rev Mal Respir 2002;19:455-466.

  3. Franklin WA. Diagnosis of lung cancer: pathology of invasive and preinvasive neoplasia. Chest 2000;117(4 suppl 1):80-89.

  4. Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 2006;86:245-278.

  5. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 2001;6:339-353.

  6. Liu B, Lague JR, Nunes DP, et ál. Expression of membrane-associated mucin MUC1 and MUC4 in major human salivary glands. J Histochem Cytochem 2002;50:811-820.

  7. Hilkens J, Ligtenberg MJ, Vos HL, Litvinov SV. Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci 1992;17:359-363.

  8. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci USA 2002;99:10231-10233.

  9. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004;4:45-60.

  10. Mouritsen S, Meldal M, Christiansen-Brams I, Elsner H, Werdelin O. Attachment of oligosaccharides to peptide antigen profoundly affects binding to major histocompatibility complex class II molecules and peptide immunogenicity. Eur J Immunol 1994;24:1066-1072.

  11. Laidler P, Lityn´ ska A. Tumor cell N-glycans in metastasis. Acta Biochim Pol 1997;44:343-357.

  12. Couldrey C, Green JE. Metastases: the glycan connection. Breast Cancer Res 2000;2:321-323.

  13. Ciborowski P, Finn OJ. Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis. Clin Exp Metastasis 2002;19:339-345.

  14. Bagriacik EU, Miller KS. Cell surface sialic acid and the regulation of immune cell interactions: the neuraminidase effect reconsidered. Glycobiology 1999;9:267-275.

  15. Xu Y, Sette A, Sidney J, Gendler SJ, Franco A. Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention. Immunol Cell Biol 2005;83: 440-448.

  16. Stepensky D, Tzehoval E, Vadai E, Eisenbach L. O-glycosylated versus non-glycosylated MUC1-derived peptides as potential targets for cytotoxic immunotherapy of carcinoma. Clin Exp Immunol 2006;143: 139-149.

  17. Gendler SJ, Spicer AP. Epithelial mucin genes. Annu Rev Physiol 1995;57:607-634.

  18. Leroy X, Buisine MP, Leteurtre E, et ál. MUC1 (EMA): a key molecule of carcinogenesis? Ann Pathol 2006;26:257-266.

  19. Copin MC, Devisme L, Buisine MP, et ál. From normal respiratory mucosa to epidermoid carcinoma: expression of human mucin genes. Int J Cancer 2000;86: 162-168.

  20. Ho SB, Kim YS. Carbohydrate antigens on cancer-associated mucin-like molecules. Semin Cancer Biol 1991;2:389-400.

  21. Quinlin IS, Burnside JS, Dombrowski KE, Phillips CA, Dolby N, Wright SE. Context of MUC1 epitope: immunogenicity. Oncol Rep 2007;17:453-456.

  22. Reis CA, David L, Seixas M, Burchell J, Sobrinho-Simões M. Expression of fully and under-glycosylated forms of MUC1 mucin in gastric carcinoma. Int J Cancer 1998;79:402-410.

  23. Yonezawa S, Sato E. Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol Int 1997;47:813-830.

  24. Fernandez-Rodriguez J, Dwir O, Alon R, Hansson GC. Tumor cell MUC1 and CD43 are glycosylated differently with sialyl-Lewis a and x epitopes and show variable interactions with E-selectin under physiological flow conditions. Glycoconj J 2001;18:925-930.

  25. Sheehan DC, Hrapchack BB. Theory and practice of histotechnology. 2nd ed. St Louis: Mosby; 1980.p. 196-197.

  26. Loughlin PM, Cooke TG, George WD, Gray AJ, Stott DI, Going JJ. Quantifying tumour-infiltrating lymphocyte subsets: a practical immuno-histochemical method. J Immunol Methods 2007;321:32-40.

  27. Tamada S, Goto M, Nomoto M, et ál. Expression of MUC1 and MUC2 mucins in extrahepatic bile duct carcinomas: its relationship with tumor progression and prognosis. Pathol Int 2002;52:713-723.

  28. Baldus SE, Wienand JR, Werner JP, et ál. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope. Int J Oncol 2005;27:1289-1297.

  29. Irimura T, Denda K, Iida S, Takeuchi H, Kato K. Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity. J Biochem 1999;126: 975-985.

  30. Chandrasekaran EV, Xue J, Neelamegham S, Matta KL. The pattern of glycosyl- and sulfotransferase activities in cancer cell lines: a predictor of individual cancer-associated distinct carbohydrate structures for the structural identification of signature glycans. Carbohydr Res 2006;341:983-994.

  31. Wu AM, Wu JH, Shen F. Interaction of a novel Tn (GalNAc alpha 1—>Ser/Thr) glycoprotein with Gal, GalNAc and GlcNAc specific lectins. Biochem Biophys Res Commun 1994;198:251-256.

  32. Peracaula R, Barrabés S, Sarrats A, Rudd PM, de Llorens R. Altered glycosylation in tumours focused to cancer diagnosis. Dis Markers 2008;25:207-218.

  33. Brockhausen I. Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta 1999;1473:67-95.

  34. Amaya S, Sasaki M, Watanabe Y, et ál. Expression of MUC1 and MUC2 and carbohydrate antigen Tn change during malignant transformation of biliary papillomatosis. Histopathology 2001;38:550-560.

  35. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001;91: 1973-1982.

  36. Croce MV, Isla-Larrain M, Tur R, Rabassa ME, Segal-Eiras A. Antigenic differences between metastatic cells in bone marrow and primary tumours and the anti-MUC1 humoral immune response induced in breast cancer patients. Clin Exp Metastasis 2004;21:139-147.




2020     |     www.medigraphic.com